Journal article
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group
Abstract
AT7519M is a small molecule inhibitor of cyclin-dependent kinases 1, 2, 4, 5, and 9 with in vitro activity against lymphoid malignancies. In two concurrent Phase II trials, we evaluated AT7519M in relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) using the recommended Phase II dosing of 27 mg/m2 twice weekly for 2 of every 3 weeks. Primary objective was objective response rate (ORR). Nineteen patients were …
Authors
Seftel MD; Kuruvilla J; Kouroukis T; Banerji V; Fraser G; Crump M; Kumar R; Chalchal HI; Salim M; Laister RC
Journal
Leukemia & Lymphoma, Vol. 58, No. 6, pp. 1358–1365
Publisher
Taylor & Francis
Publication Date
June 3, 2017
DOI
10.1080/10428194.2016.1239259
ISSN
1042-8194
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkersCanadaChromosome AberrationsCombined Modality TherapyCyclin-Dependent KinasesDrug Resistance, NeoplasmFemaleHumansLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-CellMaleMiddle AgedNeoplasm StagingProtein Kinase InhibitorsRecurrenceRetreatment